TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05131308

Intervention type: OTHER
Intervention: leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA
Description: All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.

Intervention type: OTHER
Intervention: leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA
Description: All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.

Intervention type: OTHER
Intervention: leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA
Description: All patients were evaluated and followed with imaging, and per investigators' respective clinical judgement, then proceeded to have an intervention for leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA.
Study: NCT02105922

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protein Whey
Description: Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
Study: NCT00790816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in combination with an anti-cancer agent
Description: Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
Study: NCT02453737

Intervention type: RADIATION
Group type: OTHER
Intervention: Brachytherapy APBI

Intervention type: RADIATION
Group type: OTHER
Intervention: 3D-CRT (photon) APBI

Intervention type: RADIATION
Group type: OTHER
Intervention: Proton APBI
Study: NCT04338321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 28 mg
Description: Esketamine will be self-administered at a dose of 28 mg as nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg
Description: Esketamine will be self-administered at a dose of 56 mg as nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR 50 mg
Description: Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR 100 mg
Description: Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR 150 mg
Description: Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI/SNRI
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI/SNRI
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
Study: NCT05476289

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01263769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Starting dose: 5 mg by mouth twice each day for 12 weeks.
Study: NCT02052778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle
Study: NCT00790816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib monotherapy
Study: NCT02052778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: oral once daily dosing, 21-day cycle
Study: NCT03748823

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab OBDS
Description: The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ravulizumab OBDS
Description: The ravulizumab OBDS is a biological-device combination product consisting of a prefilled cartridge containing ravulizumab SC and an on-body injector.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ravulizumab
Description: Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered by IV infusion. Ravulizumab IV doses will be based on participant body weight.
Study: NCT03567733

Intervention type: DEVICE
Intervention: XIENCE Sierra
Description: Percutaneous coronary intervention
Study: NCT06312150

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of peripheral blood (control group)
Description: Peripheral blood sample will be acquired in excess to the last scheduled control sample according to clinical practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample (Substudy-solid neoplasms)
Description: peripheral blood sample, bone marrow aspirate and fresh or paraffin biopsia tissutale will be collected for the substudy

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample (substudy-leukaemia patients)
Description: sample of peripheral blood and bone marrow blood for the substudy, derived from paediatric or young adult leukaemia patients
Study: NCT00790816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Description: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Study: NCT03228602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of GEP (Gustatory Evoked Potentials)
Description: record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
Study: NCT04639388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological testing, questionnaires and experimental tasks
Description: Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological testing, questionnaires and experimental tasks
Description: Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition
Study: NCT02689518

Intervention type: DRUG
Group type: OTHER
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
Study: NCT03324191

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea beverage
Description: Tea beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea extract (medium concentration)
Description: Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea extract (high concentration)
Description: Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat liquid meal challenge
Description: A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg \[1,1,1-13C3\] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids.
Study: NCT04590885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Couple Communication Skills Training
Description: Participants attend six 60-minute sessions consisting of education and skills training to enhance cancer-related communication.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Lifestyle Information
Description: Participants attend attend six 60-minute sessions consisting of information and support across a range of cancer-related topics.
Study: NCT03541083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: prephase and consolidation (I and II)
Study: NCT03501082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L Reuteri PB-W1 Strain
Description: L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L Reuteri PB-W1 Strain
Description: L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. Reuteri DSM20016T Strain
Description: L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L. Reuteri DSM20016T Strain
Description: L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Limosilactobacillus reuteri in food grade conditions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Industrialized-Type Diet
Description: Non-industrialized-type diet will be prepared in a metabolic kitchen, with all meals and snacks provided to participants for three weeks.
Study: NCT04135807

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microdevice
Description: Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas.
Study: NCT01095549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSTM TY101 FIR emitter (Far infrared therapy)
Description: A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw\>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: A device without far infrared therapy
Study: NCT04242355

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Subjects will receive both active and sham TMS in a randomized crossover assignment involving two study sessions
Study: NCT02943174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND programme for cancer patients
Description: Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard personalized treatment of cancer

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Standard personalized treatment of cancer
Study: NCT02133495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Cadaveric Human Acellular Dermal Tissue
Study: NCT00868634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 15 mg/kg i.v., day 1 Cycles are repeated every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg i.v., day 1. Cycles are repeated every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
Study: NCT00672698

Intervention type: PROCEDURE
Intervention: SURGERY
Description: ELECTIVE SURGICAL PROCEDURES

Intervention type: PROCEDURE
Intervention: SURGERY
Description: ELECTIVE SURGICAL PROCEDURES

Intervention type: PROCEDURE
Intervention: SURGERY
Description: ELECTIVE SURGICAL PROCEDURES
Study: NCT03403803

Intervention type: DEVICE
Intervention: Optune
Description: Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.

Intervention type: DEVICE
Intervention: Optune
Description: Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.
Study: NCT01998256

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AV optimization
Description: Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV optimization
Description: Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.